We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Growth and Spread of Breast Cancer Linked to Tumor Cells' Expression of a Cartilage Protein

By LabMedica International staff writers
Posted on 27 Apr 2016
Image: High expression of COMP in breast cancer cells, seen here in brown, was associated with poor clinical prognosis for the patient. Cancer cells expressing COMP became more invasive and changed their metabolism, which allowed them to survive better and spread to other organs (Photo courtesy of Dr. Anna Blom, Lund University).
Image: High expression of COMP in breast cancer cells, seen here in brown, was associated with poor clinical prognosis for the patient. Cancer cells expressing COMP became more invasive and changed their metabolism, which allowed them to survive better and spread to other organs (Photo courtesy of Dr. Anna Blom, Lund University).
A team of Swedish cancer researchers has identified a protein in breast tumors and surrounding stromal tissue that contributes to the development and spread of the disease.

Investigators at Lund University (Malmö, Sweden) using tissue microarrays derived from two cohorts of patients with breast cancer found that the protein COMP (cartilage oligomeric matrix protein), a soluble pentameric protein expressed in cartilage and involved in collagen organization, was expressed to a varying degree in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Normal breast tissue did not express detectable levels of COMP.

The investigators injected MDA-MB-231breast cancer cells that stably expressed COMP into the mammary fat pads of SCID (CB-17/Icr-Prkdcscid/Rj) mice. They reported in the April 11, 2016, online edition of the journal Oncogene that tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control tumors that did not express the protein.

In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of the enzyme matrix metalloprotease-9. Microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. Furthermore, in vitro measurement of cell respiration indicated that COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect, in which they produced energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.

Based on these results, the investigators concluded that COMP was a novel biomarker in breast cancer, which contributed to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.

"We saw a clear association between high levels of COMP and a worse breast cancer prognosis. With more research, COMP has the potential of becoming an indicator of aggressive breast cancer, and thereby providing early and valuable information before deciding on an appropriate treatment," said senior author Dr. Anna Blom, professor of protein chemistry at Lund University.

Related Links:
Lund University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
POC Immunoassay Analyzer
Procise DX

Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more